B of A Securities analyst Julien Dumoulin-Smith downgrades FirstEnergy (NYSE:FE) from Neutral to Underperform and lowers the price target from $41 to $38.
Vistagen Receives FDA “Study May Proceed” Letter Under Its Investigational New Drug Application For PH10 To Treat Major Depressive Disorder
Vistagen, (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today